Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Liquidia Corporation (Nasdaq: LQDA) will present two posters at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain, taking place September 5-9, 2026. One poster covers baseline lung morphology patterns in ILD-PH from the ASCENT study (NCT06129240), and the other outlines Re-Spire, the Phase 3 randomized, double-blinded, placebo-controlled study evaluating L606 (treprostinil liposome inhalation suspension) in pulmonary hypertension with interstitial lung disease. Chief Medical Officer Dr. Rajeev Saggar characterized the presentations as steps in building the evidence base around the company's inhaled treprostinil programs for PH-ILD patients.
Key figures
- Phase Of Trial
- Phase 3
- Asc Trial Id
- NCT06129240
- Conference
- European Respiratory Society (ERS) 2026 Congress
- Poster Count
- 2
- Re Spire Design
- Phase 3, randomized, double-blinded, placebo-controlled study of L606 in pulmonary hypertension with interstitial lung disease (PH-ILD)
- Conference Dates
- September 5-9, 2026
- Conference Location
- Barcelona, Spain
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.